Trial Profile
A Within Group, Randomised, Phase I, Repeated Doses, Placebo and Octreotide Controlled Study in Healthy Volunteers to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Incremental Doses of ITF2984
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Somatostatin (Primary) ; Octreotide
- Indications Cancer
- Focus Adverse reactions; Pharmacodynamics
- Acronyms MAD
- 12 Jun 2013 New trial record